A study of palbociclib and fulvestrant for advanced breast cancer that has continued to grow despite hormone treatment (PYTHIA)

This study looked at adding palbociclib to a hormone treatment called fulvestrant for advanced breast cancer.

It was for post menopausal women whose:

• breast cancer had spread to another part of the body (metastatic breast cancer)

• breast cancer cells were oestrogen receptor positive (ER positive)

• breast cancer cells had low or no amounts of a protein called HER2 (HER2 negative cancer)

Women could join the study between 2018 and 2019. The team published the results in 2022.